Patents Assigned to The Government of the U.S.A., as represented by the Secretary, Dept. of Health & Human Services
  • Publication number: 20170145097
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Application
    Filed: February 3, 2017
    Publication date: May 25, 2017
    Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Publication number: 20150292023
    Abstract: Described herein are methods of preventing cancer, treating cancer, inhibiting tumor growth, predicting patient outcomes, optimizing dosage, and monitoring the efficacy of treatment. In particular, certain microRNAs and messenger RNAs are useful indicators of response to NSAID chemoprevention and therapy of patients having Lynch syndrome or hereditary non-polyposis colorectal cancer.
    Type: Application
    Filed: December 3, 2012
    Publication date: October 15, 2015
    Applicants: Ohio State Innovation Foundation, Cincinnati Children's Hospital Medical Center, The Government of the U.S.A. as Represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Richard Fishel, Carlo M. Croce, Levy Kopelovich, Bruce Aronow, Juana Martin-Lopez
  • Publication number: 20150267269
    Abstract: Provided herein are new methods, primers, and kits for genotyping HIV-1, including group M viral strains. The methods can be used for HIV-1 drug resistance surveillance and monitoring, for example in resource-poor countries. The disclosed methods can detected more mixed HIV-1 population than previous methods. Given the high efficiency in genotyping diverse HIV-1 group M viral strains from plasma and dried blood spot (DBS) samples and substantial reagent cost saving, the disclosed methods can be used for HIV-1 drug resistance genotyping in both antiretroviral therapy (ART)-naive and -experienced populations for surveillance purposes and patient monitoring.
    Type: Application
    Filed: May 22, 2015
    Publication date: September 24, 2015
    Applicant: The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Chunfu Yang, Zhiyong Zhou, Nicholas Wagar, Joshua R. DeVos
  • Publication number: 20140120134
    Abstract: The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.
    Type: Application
    Filed: December 31, 2013
    Publication date: May 1, 2014
    Applicant: The Government of The U.S.A, as represented by the Secretary. Dept. of Health and Human Services
    Inventors: Dennis J. KOPECKO, De-Qi XU
  • Publication number: 20140087398
    Abstract: Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, oxidized cardiolipins, which may be conjugated with a variety of attachment molecules, such as BSA, KLH, biotin, synthetic protein MAPS, IgY, streptavidin, or avidin, are described. Such oxidized cardiolipin, alone or complexed with one or more attachment molecules, are useful to detect anti-lipoidal antibodies (such as IgG and IgM antibodies) in subjects, for example, when used in ELISA plates. ELISA plates are described that permit the detection of anti-lipoidal antibodies and that permit the co-detection of nontreponemal and treponemal antibodies in biological samples.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 27, 2014
    Applicants: Arlington Scientific, Inc., Government of the U.S.A. as Represented by the Secretary of the Dept. of Health and Human Service
    Inventors: Arnold R. Castro, Himanshu Champaklal Mody
  • Publication number: 20140020346
    Abstract: A containment system for reducing the release of harmful respirable particles through surface openings in equipment that carries sand includes a filter-receiving member configured to be coupled over an opening in a surface of the equipment and a filter member configured to be coupled to the filter-receiving member. The filter-receiving member can have a first side, a second side, and a passageway extending from the first side to the second side. The filter can have a porosity that permits air to flow through the filter member and restricts the flow of solid particulates.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 23, 2014
    Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept of Health & Human Services
    Inventor: The Government of the U.S.A. as represented by the Secretary of the Department of Health and Human Services
  • Publication number: 20130136771
    Abstract: A substantially pure or isolated oligodeoxynucleotide of at least 10 nucleotides is disclosed, wherein the oligodeoxynucleotide comprised a sequence represented by either formula: 5? N1N2N3T-CpG-WN4N5N6 3? wherein the CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6 are nucleotides, or the formula: 5? RY-CpG-RY 3? wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host. In some embodiments, the oligodeoxynucleotide includes the nucleic acid sequences set forth as SEQ ID NO: 137.
    Type: Application
    Filed: February 5, 2013
    Publication date: May 30, 2013
    Applicant: The Government of the U.S.A as represented by the Secretary of the Dept of Health & Human Services
    Inventor: The Government of the U.S.A as represented by the Secretary of the Department of Health and Human Services
  • Publication number: 20120296243
    Abstract: Methods, devices and systems for recovering motor control of an area in the body of a patient affected by a neurological disorder. A device vibrotactilely stimulates a substitute site for the affected area thereby recovering the motor control of the affected area. The stimulation provided by the device is volitionally controlled by the patient.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 22, 2012
    Applicant: The Government of the U.S.A, as represented by the Secretary, Dept of Health and Human Services
    Inventors: Christy Leslie Ludlow, Christopher Poletto, Ianessa Humbert
  • Publication number: 20120276190
    Abstract: The present invention provides compositions comprising a chimeric molecule comprising a cytotoxin that inhibits protein synthesis and an agent that inactivates an anti-apoptotic BCL-2 family member protein and methods of inhibiting the growth of or promoting the apoptosis of an aberrantly proliferating cell population by co-administering the chimeric molecule and the agent that inactivates an anti-apoptotic BCL-2 family member protein.
    Type: Application
    Filed: February 27, 2012
    Publication date: November 1, 2012
    Applicant: The Government of the U.S.A. as Represented By the Secretary of the Dept. of Health & Human Services
    Inventor: David J. Fitzgerald
  • Publication number: 20110165623
    Abstract: Novel compositions and methods for the high efficiency production of the transforming growth factor-beta (TGF?) supergene family of peptide growth factors are provided.
    Type: Application
    Filed: January 6, 2005
    Publication date: July 7, 2011
    Applicant: THE GOVERNMENT OF THE U.S. AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES
    Inventors: Peter Daopin Sun, Zongcheng Zou
  • Publication number: 20110065185
    Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.
    Type: Application
    Filed: July 29, 2010
    Publication date: March 17, 2011
    Applicant: The Government of U.S.A as represented by the Secretary of the Dept of Health and Human Services
    Inventors: Ira H. Pastan, Giuliana Salvatore, Richard Beers, Robert J. Kreitman
  • Publication number: 20100323351
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins.
    Type: Application
    Filed: March 15, 2010
    Publication date: December 23, 2010
    Applicant: The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Curtis C. Harris, Makoto Nagashima
  • Publication number: 20100062456
    Abstract: The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.
    Type: Application
    Filed: August 20, 2009
    Publication date: March 11, 2010
    Applicants: The Regents of the University of California, The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Charles S. Zuker, Jon E. Adler, Nick Ryba, Ken Mueller, Mark Hoon
  • Publication number: 20090247473
    Abstract: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of inactivated retroviruses such as HIV, prevention of the transmission of such retroviruses, and detection of retroviral proteins.
    Type: Application
    Filed: March 30, 2009
    Publication date: October 1, 2009
    Applicant: THE GOVERNMENT OF THE U.S.A.,as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: John K. Inman, Atul Goel, Ettore Appella, Jim Turpin, Marco Schito
  • Publication number: 20090054476
    Abstract: The present invention relates to allosteric modulation of A3 adenosine receptor (A3AR) and provides for the use of an A3 adenosine receptor modulator (A3RM), for the preparation of pharmaceutical compositions for modulating the A3AR in a subject, as well as pharmaceutical compositions comprising the same and therapeutic methods comprising administering to a subject an amount of an A3RM, the amount being effective to modulate A3AR activity. The A3RM according to the invention are 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives. The invention also provides some of such novel 1H-Imidazo-[4,5-c]quinolin-4-amine derivatives.
    Type: Application
    Filed: July 28, 2008
    Publication date: February 26, 2009
    Applicants: The Government of the U.S.A., represented by The Secretary, Dept. of Health and Human Services, Unversiteit Leiden
    Inventors: Aniko Goblyos, Johannes Brussee, Adriaan P. Ijzerman, Zhan-Guo Gao, Kenneth Jacobson
  • Publication number: 20080167245
    Abstract: An isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding the metastasis suppressor gene located at p21-p12 on chromosome 8 of a human (Tey 1), a variant Tey 1, or a fragment of either of the foregoing comprising at least 455 contiguous nucleotides; an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence that is complementary to a nucleotide sequence encoding Tey 1, a variant Tey 1, or a fragment of either of the foregoing comprising at least 455 contiguous nucleotides; a vector comprising any of the foregoing, wherein, when the isolated or purifies nucleic acid molecule consists essentially of a nucleotide sequence encoding Tey 1 or a variant thereof, the isolated or purified nucleic acid molecule is optionally part of an encoded fusion protein; a cell comprising and expressing any of the foregoing isolated or purified nucleic acid molecules, optionally in the form of a vector; an isolated or purified polypeptide molecule cons
    Type: Application
    Filed: March 10, 2008
    Publication date: July 10, 2008
    Applicant: The Government of the U.S.A., as represented by the Secretary , Dept. of Health & Human Services
    Inventors: Naoki Nihei, J. Carl Barrett, Natalay Kouprina, Vladimir Larionov
  • Publication number: 20080039448
    Abstract: A compound of formula I: or solvate thereof, wherein n is 1 to 10, and M and M? are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.
    Type: Application
    Filed: January 20, 2006
    Publication date: February 14, 2008
    Applicant: GOVERNMENT OF THE U.S.A. REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Paul Liu, B. Vishnuvajjala, Kenneth Snader, David Thurston, Philip Howard, Stephen Gregson
  • Publication number: 20070180543
    Abstract: The present invention provides methods and compositions for drug screens to identify and characterize agents that are agonistic or antagonistic to activation of the promoter region of the NAG-1 gone. Activation of the NAG-1 gene is associated with the apoptotic elimination of cancer cells both in vitro and in vivo. The invention also provides novel promoter region sequences of the NAG-1 gene.
    Type: Application
    Filed: November 27, 2006
    Publication date: August 2, 2007
    Applicant: Government of the U.S.A, represented by the Secretary, Dept. of Health & Human Services
    Inventors: Thomas Eling, Seung Baek
  • Publication number: 20070099271
    Abstract: The invention provides an isolated or purified nucleic acid molecules consisting essentially of the nucleotide sequence encoding either transductin-1 (TDC1) or transductin-2 (TDC2), related and derivative nucleic acid molecules vectors comprising the isolated or purified nucleic acid sequences, cells comprising such vectors, polypeptides encoded by the nucleic acid molecules, monoclonal antibodies and cell lines producing the monoclonal antibodies. The invention also provides methods of treating, prognosticating and monitoring hearing loss.
    Type: Application
    Filed: December 22, 2006
    Publication date: May 3, 2007
    Applicant: Government of the U.S.A., represented by the Secretary, Dept.of Health & Human Services
    Inventors: Andrew Griffith, Kiyoto Kurima, Edward Wilcox, Thomas Friedman
  • Publication number: 20060292627
    Abstract: A novel gene, PB39, that is up-regulated, or over-expressed, in prostate cancer has been identified. The gene has been identified by means of its cDNA obtained by reverse transcription of the corresponding mRNA. Microdissection of prostate glands that had been surgically removed from prostate cancer patients revealed a novel up-regulated transcript in an aggressive prostate carcinoma. Differential analysis for the presence of this gene was carried out from the same glands by comparing tanscription in microdissected normal prostatic epithelium versus that in microdissected invasive tumor. The transcript was over-expressed in 5 of 10 prostate carcinomas examined. A variant transcript was over-expressed in 4 of 4 prostate carcinomas, and was found in 1 of 4 normal samples.
    Type: Application
    Filed: August 29, 2006
    Publication date: December 28, 2006
    Applicant: Government of the U.S.A., as represented by the Secretary, Dept. of Health & Human Services
    Inventors: Rodrigo Chuaqui, Kristina Cole, Lance Liotta, Michael Emmert-Buck